Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Victory Capital Management Inc. lowered its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 1.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 361,386 shares of the biopharmaceutical company’s stock after selling 6,760 shares during the period. Victory Capital Management Inc. owned about 0.55% of Regulus Therapeutics worth $645,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics during the 2nd quarter valued at $136,000. Bank of New York Mellon Corp acquired a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at $352,000. Opaleye Management Inc. acquired a new stake in shares of Regulus Therapeutics in the 1st quarter valued at $490,000. RA Capital Management L.P. acquired a new stake in shares of Regulus Therapeutics in the 1st quarter valued at $18,000,000. Finally, NEA Management Company LLC acquired a new stake in shares of Regulus Therapeutics in the 1st quarter valued at $18,627,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Price Performance

Shares of RGLS opened at $1.82 on Monday. The company has a market capitalization of $119.15 million, a PE ratio of -1.25 and a beta of 1.63. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79. The company’s fifty day moving average price is $1.64 and its 200 day moving average price is $2.05.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). Analysts anticipate that Regulus Therapeutics Inc. will post -0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

RGLS has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price objective on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. Finally, StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.